The optimized cabozantinib population pharmacokinetic (POPPK) model derived from the POPPK model from the registration study adequately predicts real-world cabozantinib pharmacokinetic data.

A barrier for wider use of cabozantinib are the relatively high costs associated with its use, irrespective of the used dose since a flat-pricing model (same price for different strengths) is implemented.

The developed alternative dosing regimens have the potential to save up to approximately 66.7% in drug expenses while maintaining adequate exposure.